Choose Language
Select a language for news translation.
Two drugs make up nearly two-thirds of Eli Lilly 's (NYSE: LLY) top line, generating around $12.8 billion in revenues in the first quarter of 2026. The two dru…
Written by Reuben Gregg Brewer for The Motley Fool -> Eli Lilly is probably best known for its dominant GLP-1 drugs right now. The company's recent $3.8 bill…
Written by Robert Izquierdo for The Motley Fool -> Dennis Cho sold 14,205 shares on May 29, 2026, for a total transaction value of ~$991,000, at a reported pr…
The S&P 500 index (SNPINDEX: ^GSPC) has a tiny yield of 1.1%. The average pharmaceutical company's yield is 1.7%. Those comparison points make Pfizer 's (NYSE:…
Written by Manali Pradhan for The Motley Fool -> Alphabet offers investors exposure to AI, robotaxis, and SpaceX through one profitable megacap stock. Waymo’…
Written by Adam Spatacco for The Motley Fool -> SpaceX recently set a fixed price of $135 on its IPO shares. The company is targeting a valuation near $1.8 t…
Written by Reuben Gregg Brewer for The Motley Fool -> Brookfield Corporation is a large and respected Canadian asset manager. The company is buying back its …
Study after study suggests that consistently beating the market through stock picking is exceptionally difficult. Yet in 2026, retail investors are putting tha…
SpaceX's S-1 reveals $18.7B in 2025 revenue, with Starlink hitting 10.3M subscribers and 50% growth as the core IPO value driver. NVDA 's 18,311% decade retur…
When retail investors watch mega-cap hyperscalers pull the broad indexes into a concentrated corner, the natural, contrarian response is to look downstream. B…
Written by Harsh Chauhan for The Motley Fool -> Nvidia and Sandisk are in the middle of the AI infrastructure boom, driven by the terrific demand for their ch…
